Zogenix Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
20 déc. 2013 16h15 HE
|
Zogenix
SAN DIEGO, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team
17 déc. 2013 08h30 HE
|
Zogenix
SAN DIEGO, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Reports Granting of Inducement Awards
11 déc. 2013 07h30 HE
|
Zogenix
SAN DIEGO, Dec. 11, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Announces FDA Approval of 4 mg SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-Free Delivery System
10 déc. 2013 08h30 HE
|
Zogenix
SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders...
Zogenix to Present at the Oppenheimer 24th Annual Healthcare Conference
04 déc. 2013 07h30 HE
|
Zogenix
SAN DIEGO, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system...
Zogenix and Battelle Expand DosePro Technology Business Agreement
03 déc. 2013 07h30 HE
|
Zogenix
SAN DIEGO and COLUMBUS, Ohio, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle today announced that they have entered into a new long-term collaborative agreement regarding...
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
12 nov. 2013 16h30 HE
|
Zogenix
SAN DIEGO, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Prices Public Offering of Common Stock
05 nov. 2013 19h50 HE
|
Zogenix
SAN DIEGO, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Announces Proposed Public Offering of Common Stock
04 nov. 2013 06h51 HE
|
Zogenix
SAN DIEGO, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Reports Third Quarter 2013 Financial Results
04 nov. 2013 06h00 HE
|
Zogenix
Business Highlights and Milestones
Received FDA Approval for Zohydro™ ER (hydrocodone bitartrate), an extended-release oral formulation of hydrocodone without acetaminophen
Announced...